\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ \\ bilateral\\ proptosis\\,\\ mild\\ periorbital\\ edema\\,\\ sclera\\ clear\\,\\ perrla\\,\\ eomi\\,\\ no\\ discharge\ \(0\)\
\-\ treatment\\ for\\ grave\\'s\\ ophthalmopathy\\ depends\\ on\\ severity\\ of\\ symptoms\\.\\ \\ if\\ present\\,\\ treat\\ hyperthyroidism\\ with\\ methimazole\\.\\ \\ for\\ mild\\ involvement\\ including\\ dry\\,\\ irritated\\ eyes\\,\\ natural\\ tears\\ are\\ helpful\\ during\\ the\\ day\\ and\\ an\\ eye\\ lubricant\\ \\(methycellulose\\)\\ is\\ appropriate\\ at\\ night\\.\\ \\ for\\ moderate\\ disease\\ that\\ can\\ include\\ conjunctival\\ erythema\\,\\ progressive\\ proptosis\\,\\ and\\ diplopia\\,\\ prednisone\\ 30mg\\ daily\\ for\\ 4\\ weeks\\ should\\ be\\ initiated\\ additionally\\.\\ \\ \ \(0\)\
\-\ external\\ radiation\\ may\\ be\\ used\\ in\\ conjunction\\ with\\ prednisone\\ if\\ high\\ dose\\ is\\ contraindicated\\ or\\ not\\ tolerated\\ in\\ the\\ case\\ of\\ persistent\\ orbital\\ edema\\.\\ \\ \ \(0\)\
\-\ in\\ severe\\ disease\\ in\\ which\\ the\\ patient\\ presents\\ with\\ threatened\\ loss\\ or\\ complete\\ loss\\ of\\ vision\\,\\ initial\\ pulse\\ therapy\\ with\\ intravenous\\ methylprednisone\\ or\\ immediate\\ intramuscular\\ dexamethasone\\ 4mg\\ may\\ be\\ done\\ before\\ urgent\\ orbital\\ decompression\\ surgery\\.\\ \\ surgery\\ is\\ also\\ indicated\\ for\\ refractory\\ disease\\ despite\\ glucocorticoids\\ or\\ cosmetic\\ correction\\ of\\ severe\\ proptosis\\.\\ \\ \ \(0\)\
\-\ the\\ orbit\\ may\\ be\\ decompressed\\ transantrally\\,\\ which\\ involves\\ removal\\ of\\ medial\\ wall\\ and\\ floor\\ of\\ the\\ orbits\\.\\ \\ this\\ procedure\\ is\\ preferred\\ over\\ others\\ because\\ it\\ does\\ not\\ involve\\ craniotomy\\ or\\ extensive\\ scarring\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ follow\\-up\\ should\\ include\\ monthly\\ clinic\\ visits\\ that\\ may\\ be\\ progressively\\ spaced\\ out\\ to\\ 3\\ months\\,\\ 6\\ months\\,\\ or\\ 12\\ months\\ \\-\\ depending\\ on\\ patient\\'s\\ clinical\\ course\\ and\\ severity\\ of\\ disease\\.\\ \\ regular\\ follow\\-up\\ with\\ ophthalmology\\,\\ endocrinology\\,\\ and\\ surgery\\ as\\ needed\\,\\ particularly\\ if\\ patient\\ has\\ persistent\\ or\\ worsening\\ symptoms\\,\\ and\\ especially\\ if\\ disease\\ complications\\ are\\ anticipated\\.\ \(0\)\
\-\ \\â\\€\\¢\\ bilateral\\ proptosis\\ and\\ periorbital\\ tissue\\ edema\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ inferior\\ recti\\ muscles\ \(0\)\
\-\ \\â\\€\\¢\\ increased\\ periorbital\\ fat\\ distribution\ \(0\)\
\-\ \\â\\€\\¢\\ bellies\\ of\\ medial\\ recti\\ enlarged\\ with\\ normal\\ tapering\\ of\\ tendons\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ superior\\,\\ medial\\,\\ inferior\\ rectus\\ muscles\ \(0\)\
\-\ grave\\'s\\ ophthalmopathy\ \(0\)\
\-\ \\â\\€\\¢\\ periorbital\\ \\/\\ orbital\\ cellulitis\ \(0\)\
\-\ \\â\\€\\¢\\ histiocytosis\ \(0\)\
\-\ \\â\\€\\¢\\ orbital\\ myositis\\ \\/\\ orbital\\ pseudotumor\ \(0\)\
\-\ \\â\\€\\¢\\ grave\\â\\€\\™s\\ orbitopathy\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ 45\\ year\\-old\\ man\\ with\\ a\\ past\\ history\\ of\\ malignant\\ testicular\\ neoplasm\\ and\\ hashimoto\\â\\€\\™s\\ thyroiditis\\,\\ presents\\ now\\ with\\ a\\ several\\-month\\ history\\ of\\ worsening\\ eye\\ swelling\\,\\ dryness\\,\\ and\\ irritation\\,\\ gradually\\ progressing\\ to\\ lid\\ retraction\\ and\\ intermittent\\ blurry\\ vision\\,\\ prompting\\ a\\ referral\\ to\\ ophthalmology\\.\\ \\ he\\ denies\\ recent\\ trauma\\,\\ fever\\,\\ chills\\,\\ nausea\\,\\ headaches\\.\ \(0\)\
\-\ the\\ patient\\ has\\ grave\\â\\€\\™s\\ ophthalmopathy\\,\\ but\\ he\\ does\\ not\\ have\\ symptoms\\ of\\ hyperthyroidism\\ such\\ as\\ heat\\ intolerance\\,\\ tachycardia\\,\\ heart\\ palpitations\\,\\ tremors\\,\\ anxiousness\\,\\ and\\ unintentional\\ weight\\ loss\\.\\ \\ rather\\,\\ he\\ is\\ clinically\\ hypothyroid\\ and\\ requires\\ synthroid\\ treatment\\.\\ \\ with\\ his\\ past\\ history\\ of\\ hashimoto\\'s\\ thyroiditis\\ and\\ subsequent\\ thyroid\\ ablation\\ therapy\\,\\ the\\ patient\\ may\\ have\\ little\\ functional\\ thyroid\\ tissue\\ left\\ for\\ clinical\\ manifestations\\ of\\ hyperthyroidism\\ as\\ a\\ result\\ of\\ his\\ grave\\'s\\ disease\\.\\ \\ however\\,\\ the\\ thyroid\\ stimulating\\ hormone\\ receptor\\ \\(tshr\\)\\ autoantibodies\\ are\\ still\\ circulating\\ and\\ affect\\ other\\ cell\\ types\\ with\\ tshr\\ antigens\\ such\\ as\\ fibroblasts\\,\\ adipocytes\\,\\ and\\ t\\-cells\\ contributing\\ to\\ tissue\\ proliferation\\,\\ inflammation\\ and\\ edema\\ consistent\\ with\\ grave\\'s\\ ophthalmopathy\\ and\\ pretibial\\ myxedema\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ grave\\:\\ 0\\.07304552047129036\ \(0\)\
\-\ ophthalmopathy\\:\\ 0\\.04808130051157663\ \(0\)\
\-\ periorbital\\:\\ 0\\.04369249390797961\ \(0\)\
\-\ orbital\\:\\ 0\\.038974466242007136\ \(0\)\
\-\ proptosis\\:\\ 0\\.036711285816399604\ \(0\)\
\-\ tshr\\:\\ 0\\.03390584009217884\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.03184431668055098\ \(0\)\
\-\ recti\\:\\ 0\\.03123988939771751\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.030134891376843997\ \(0\)\
\-\ hashimoto\\:\\ 0\\.023755619593658614\ \(0\)\
\-\ ophthalmology\\:\\ 0\\.022196138408627213\ \(0\)\
\-\ \\,\\:\\ 0\\.021865043753319366\ \(0\)\
\-\ \\'s\\:\\ 0\\.021738999442696673\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.0206981969980052\ \(0\)\
\-\ thyroid\\:\\ 0\\.020205648720719487\ \(0\)\
\-\ prednisone\\:\\ 0\\.019439685801049753\ \(0\)\
\-\ edema\\:\\ 0\\.01859171914947147\ \(0\)\
\-\ may\\:\\ 0\\.018022388162481962\ \(0\)\
\-\ severity\\:\\ 0\\.01785050443873408\ \(0\)\
\-\ if\\:\\ 0\\.017836487952158735\ \(0\)\
\-\ methycellulose\\:\\ 0\\.01695292004608942\ \(0\)\
\-\ transantrally\\:\\ 0\\.01695292004608942\ \(0\)\
\-\ several\\-month\\:\\ 0\\.01695292004608942\ \(0\)\
\-\ anxiousness\\:\\ 0\\.01695292004608942\ \(0\)\
\-\ adipocytes\\:\\ 0\\.01695292004608942\ \(0\)\
\-\ t\\-cells\\:\\ 0\\.01695292004608942\ \(0\)\
\-\ enlarged\\:\\ 0\\.01682089079067696\ \(0\)\
\-\ \\/\\:\\ 0\\.016232302207045805\ \(0\)\
\-\ disease\\:\\ 0\\.01611620239864274\ \(0\)\
\-\ medial\\:\\ 0\\.015769035655327224\ \(0\)\
\-\ lubricant\\:\\ 0\\.015619944698858756\ \(0\)\
\-\ 30mg\\:\\ 0\\.015619944698858756\ \(0\)\
\-\ methylprednisone\\:\\ 0\\.015619944698858756\ \(0\)\
\-\ 4mg\\:\\ 0\\.015619944698858756\ \(0\)\
\-\ dryness\\:\\ 0\\.015619944698858756\ \(0\)\
\-\ autoantibodies\\:\\ 0\\.015619944698858756\ \(0\)\
\-\ vision\\:\\ 0\\.015184553744272753\ \(0\)\
\-\ muscles\\:\\ 0\\.01501101360857864\ \(0\)\
\-\ myxedema\\:\\ 0\\.014840204106343055\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.014734769651800707\ \(0\)\
\-\ loss\\:\\ 0\\.01431037022577946\ \(0\)\
\-\ methimazole\\:\\ 0\\.014286969351628093\ \(0\)\
\-\ irritated\\:\\ 0\\.014286969351628093\ \(0\)\
\-\ threatened\\:\\ 0\\.014286969351628093\ \(0\)\
\-\ spaced\\:\\ 0\\.014286969351628093\ \(0\)\
\-\ hypothyroid\\:\\ 0\\.014286969351628093\ \(0\)\
\-\ s\\:\\ 0\\.014139044233353387\ \(0\)\
\-\ bellies\\:\\ 0\\.013857847137562305\ \(0\)\
\-\ antigens\\:\\ 0\\.013857847137562305\ \(0\)\
\-\ eye\\:\\ 0\\.013786191565815046\ \(0\)\
\-\ he\\:\\ 0\\.01375492697326742\ \(0\)\
\-\ dexamethasone\\:\\ 0\\.01350722875911239\ \(0\)\
\-\ orbitopathy\\:\\ 0\\.01350722875911239\ \(0\)\
\-\ pretibial\\:\\ 0\\.01350722875911239\ \(0\)\
\-\ or\\:\\ 0\\.01348203700528068\ \(0\)\
\-\ months\\:\\ 0\\.013465045930904236\ \(0\)\
\-\ anticipated\\:\\ 0\\.013210785144059971\ \(0\)\
\-\ circulating\\:\\ 0\\.013210785144059971\ \(0\)\
\-\ persistent\\:\\ 0\\.013109025586563\ \(0\)\
\-\ tremors\\:\\ 0\\.012953994004397429\ \(0\)\
\-\ fibroblasts\\:\\ 0\\.012953994004397429\ \(0\)\
\-\ worsening\\:\\ 0\\.012940307578464608\ \(0\)\
\-\ be\\:\\ 0\\.012670737724460857\ \(0\)\
\-\ conjunctival\\:\\ 0\\.01252487179033164\ \(0\)\
\-\ stimulating\\:\\ 0\\.01252487179033164\ \(0\)\
\-\ monthly\\:\\ 0\\.012341582983015631\ \(0\)\
\-\ unintentional\\:\\ 0\\.012341582983015631\ \(0\)\
\-\ symptoms\\:\\ 0\\.012286485443643112\ \(0\)\
\-\ prompting\\:\\ 0\\.012174253411881726\ \(0\)\
\-\ synthroid\\:\\ 0\\.012174253411881726\ \(0\)\
\-\ receptor\\:\\ 0\\.012174253411881726\ \(0\)\
\-\ cosmetic\\:\\ 0\\.012020325127894157\ \(0\)\
\-\ blurry\\:\\ 0\\.012020325127894157\ \(0\)\
\-\ surgery\\:\\ 0\\.011971148448232357\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.011877809796829307\ \(0\)\
\-\ lid\\:\\ 0\\.011877809796829307\ \(0\)\
\-\ intramuscular\\:\\ 0\\.011745131197815938\ \(0\)\
\-\ decompressed\\:\\ 0\\.011745131197815938\ \(0\)\
\-\ visits\\:\\ 0\\.011745131197815938\ \(0\)\
\-\ endocrinology\\:\\ 0\\.011745131197815938\ \(0\)\
\-\ tissue\\:\\ 0\\.011685122241072656\ \(0\)\
\-\ contraindicated\\:\\ 0\\.011621018657166764\ \(0\)\
\-\ urgent\\:\\ 0\\.011621018657166764\ \(0\)\
\-\ sclera\\:\\ 0\\.011290537393846266\ \(0\)\
\-\ tapering\\:\\ 0\\.011290537393846266\ \(0\)\
\-\ does\\:\\ 0\\.011213927193784641\ \(0\)\
\-\ conjunction\\:\\ 0\\.011191896443100976\ \(0\)\
\-\ inferior\\:\\ 0\\.011151216774457936\ \(0\)\
\-\ irritation\\:\\ 0\\.011098069204313606\ \(0\)\
\-\ palpitations\\:\\ 0\\.011008607635784966\ \(0\)\
\-\ contributing\\:\\ 0\\.011008607635784966\ \(0\)\
\-\ depends\\:\\ 0\\.010923123476994902\ \(0\)\
\-\ natural\\:\\ 0\\.010923123476994902\ \(0\)\
\-\ progressing\\:\\ 0\\.010841278064651062\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.010692449967083623\ \(0\)\
\-\ orbits\\:\\ 0\\.010687349780663493\ \(0\)\
\-\ perrla\\:\\ 0\\.010614772226850326\ \(0\)\
\-\ should\\:\\ 0\\.010477725161110769\ \(0\)\
\-\ past\\:\\ 0\\.01044307489210167\ \(0\)\
\-\ myositis\\:\\ 0\\.010412155850585275\ \(0\)\
\-\ retraction\\:\\ 0\\.010412155850585275\ \(0\)\
\-\ tolerated\\:\\ 0\\.0103490984990026\ \(0\)\
\-\ heat\\:\\ 0\\.0102880433099361\ \(0\)\
\-\ ablation\\:\\ 0\\.0102880433099361\ \(0\)\
\-\ such\\:\\ 0\\.010274356884003279\ \(0\)\
\-\ intolerance\\:\\ 0\\.010228867043269266\ \(0\)\
\-\ refractory\\:\\ 0\\.010171457498750648\ \(0\)\
\-\ eomi\\:\\ 0\\.010115712235532854\ \(0\)\
\-\ initiated\\:\\ 0\\.010115712235532854\ \(0\)\
\-\ severe\\:\\ 0\\.010112730000253863\ \(0\)\
\-\ clinical\\:\\ 0\\.010112730000253863\ \(0\)\
\-\ tendons\\:\\ 0\\.010008847137158218\ \(0\)\
\-\ as\\:\\ 0\\.009942903891493292\ \(0\)\
\-\ proliferation\\:\\ 0\\.009907609188147794\ \(0\)\
\-\ craniotomy\\:\\ 0\\.009858921095870311\ \(0\)\
\-\ dry\\:\\ 0\\.009765093857082942\ \(0\)\
\-\ preferred\\:\\ 0\\.009765093857082942\ \(0\)\
\-\ cellulitis\\:\\ 0\\.009765093857082942\ \(0\)\
\-\ tears\\:\\ 0\\.009719842900524876\ \(0\)\
\-\ others\\:\\ 0\\.009675632288554302\ \(0\)\
\-\ diplopia\\:\\ 0\\.009590148129764237\ \(0\)\
\-\ scarring\\:\\ 0\\.009590148129764237\ \(0\)\
\-\ gradually\\:\\ 0\\.009548790042800846\ \(0\)\
\-\ rectus\\:\\ 0\\.0095083027174204\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.0095083027174204\ \(0\)\
\-\ his\\:\\ 0\\.009472650106334354\ \(0\)\
\-\ affect\\:\\ 0\\.009468650242030523\ \(0\)\
\-\ correction\\:\\ 0\\.009391716906234948\ \(0\)\
\-\ tachycardia\\:\\ 0\\.009354374433432828\ \(0\)\
\-\ manifestations\\:\\ 0\\.009354374433432828\ \(0\)\
\-\ referral\\:\\ 0\\.009317743289258417\ \(0\)\
\-\ hormone\\:\\ 0\\.009317743289258417\ \(0\)\
\-\ treat\\:\\ 0\\.009281796879619662\ \(0\)\
\-\ floor\\:\\ 0\\.009246510074488514\ \(0\)\
\-\ include\\:\\ 0\\.009219821107808796\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.009144375795038615\ \(0\)\
\-\ functional\\:\\ 0\\.009047393384217667\ \(0\)\
\-\ little\\:\\ 0\\.00892525221936704\ \(0\)\
\-\ eyes\\:\\ 0\\.008838482151519984\ \(0\)\
\-\ progressively\\:\\ 0\\.008838482151519984\ \(0\)\
\-\ therapy\\:\\ 0\\.00878707998554082\ \(0\)\
\-\ requires\\:\\ 0\\.008728562124904698\ \(0\)\
\-\ decompression\\:\\ 0\\.008702036505419437\ \(0\)\
\-\ mild\\:\\ 0\\.00865482097665822\ \(0\)\
\-\ dose\\:\\ 0\\.008599448080986182\ \(0\)\
\-\ immediate\\:\\ 0\\.008599448080986182\ \(0\)\
\-\ depending\\:\\ 0\\.00855013571442207\ \(0\)\
\-\ helpful\\:\\ 0\\.008502056287103961\ \(0\)\
\-\ daily\\:\\ 0\\.008502056287103961\ \(0\)\
\-\ pulse\\:\\ 0\\.008478459955196626\ \(0\)\
\-\ particularly\\:\\ 0\\.008478459955196626\ \(0\)\
\-\ testicular\\:\\ 0\\.008432118509852277\ \(0\)\
\-\ for\\:\\ 0\\.008412786330492868\ \(0\)\
\-\ types\\:\\ 0\\.008386867553294212\ \(0\)\
\-\ orbit\\:\\ 0\\.008278190225864708\ \(0\)\
\-\ patient\\:\\ 0\\.008236460874196038\ \(0\)\
\-\ chills\\:\\ 0\\.008215814695570181\ \(0\)\
\-\ intravenous\\:\\ 0\\.008155398933582915\ \(0\)\
\-\ erythema\\:\\ 0\\.008077688282933152\ \(0\)\
\-\ night\\:\\ 0\\.007984767942027753\ \(0\)\
\-\ bilateral\\:\\ 0\\.007976222035824786\ \(0\)\
\-\ discharge\\:\\ 0\\.007966710749047291\ \(0\)\
\-\ still\\:\\ 0\\.007828050568467785\ \(0\)\
\-\ rather\\:\\ 0\\.00781140044780795\ \(0\)\
\-\ appropriate\\:\\ 0\\.007746205156123948\ \(0\)\
\-\ involve\\:\\ 0\\.007746205156123948\ \(0\)\
\-\ despite\\:\\ 0\\.007637175649053668\ \(0\)\
\-\ involves\\:\\ 0\\.007637175649053668\ \(0\)\
\-\ 45\\:\\ 0\\.007592276872136376\ \(0\)\
\-\ regular\\:\\ 0\\.007577540578394898\ \(0\)\
\-\ distribution\\:\\ 0\\.0073955867776740345\ \(0\)\
\-\ pe\\:\\ 0\\.007382278233742161\ \(0\)\
\-\ clinic\\:\\ 0\\.007342896442696891\ \(0\)\
\-\ clinically\\:\\ 0\\.007205027349512052\ \(0\)\
\-\ needed\\:\\ 0\\.007157246582999492\ \(0\)\
\-\ not\\:\\ 0\\.007123953875434243\ \(0\)\
\-\ additionally\\:\\ 0\\.007122174299249914\ \(0\)\
\-\ have\\:\\ 0\\.0071170695321734305\ \(0\)\
\-\ indicated\\:\\ 0\\.007110624252980276\ \(0\)\
\-\ intermittent\\:\\ 0\\.007053892206063549\ \(0\)\
\-\ external\\:\\ 0\\.0069879516801431025\ \(0\)\
\-\ inflammation\\:\\ 0\\.0069879516801431025\ \(0\)\
\-\ before\\:\\ 0\\.006955810370578217\ \(0\)\
\-\ denies\\:\\ 0\\.006934677444471303\ \(0\)\
\-\ procedure\\:\\ 0\\.006882839348339518\ \(0\)\
\-\ done\\:\\ 0\\.0068125362796206766\ \(0\)\
\-\ history\\:\\ 0\\.0068089300252331736\ \(0\)\
\-\ especially\\:\\ 0\\.006763848187343196\ \(0\)\
\-\ 12\\:\\ 0\\.006725766211773619\ \(0\)\
\-\ are\\:\\ 0\\.00672042618767078\ \(0\)\
\-\ presents\\:\\ 0\\.006714016521184331\ \(0\)\
\-\ treatment\\:\\ 0\\.006652372921541873\ \(0\)\
\-\ nausea\\:\\ 0\\.006615846185158333\ \(0\)\
\-\ extensive\\:\\ 0\\.006571837927786049\ \(0\)\
\-\ complications\\:\\ 0\\.006511870759638572\ \(0\)\
\-\ progressive\\:\\ 0\\.006495075221237121\ \(0\)\
\-\ removal\\:\\ 0\\.006478425100577285\ \(0\)\
\-\ moderate\\:\\ 0\\.006461917901170763\ \(0\)\
\-\ subsequent\\:\\ 0\\.006397270572711176\ \(0\)\
\-\ used\\:\\ 0\\.0063042003018230035\ \(0\)\
\-\ result\\:\\ 0\\.0063042003018230035\ \(0\)\
\-\ headaches\\:\\ 0\\.006281619882829381\ \(0\)\
\-\ course\\:\\ 0\\.006201022006645464\ \(0\)\
\-\ has\\:\\ 0\\.006171922963439531\ \(0\)\
\-\ which\\:\\ 0\\.006135171489394418\ \(0\)\
\-\ clear\\:\\ 0\\.006076012717589703\ \(0\)\
\-\ year\\-old\\:\\ 0\\.006036085810958109\ \(0\)\
\-\ involvement\\:\\ 0\\.006022958955053494\ \(0\)\
\-\ malignant\\:\\ 0\\.005939751300729426\ \(0\)\
\-\ including\\:\\ 0\\.005933497386524854\ \(0\)\
\-\ weight\\:\\ 0\\.005890280356040126\ \(0\)\
\-\ and\\:\\ 0\\.005884909802784065\ \(0\)\
\-\ complete\\:\\ 0\\.00578341525766549\ \(0\)\
\-\ because\\:\\ 0\\.0057490736857424\ \(0\)\
\-\ heart\\:\\ 0\\.005709768555593796\ \(0\)\
\-\ that\\:\\ 0\\.005676848955995475\ \(0\)\
\-\ now\\:\\ 0\\.0056175299801954764\ \(0\)\
\-\ neoplasm\\:\\ 0\\.005596454953676785\ \(0\)\
\-\ fever\\:\\ 0\\.005560120435676858\ \(0\)\
\-\ recent\\:\\ 0\\.005524459709307303\ \(0\)\
\-\ swelling\\:\\ 0\\.005474636276886794\ \(0\)\
\-\ initial\\:\\ 0\\.005445350275537131\ \(0\)\
\-\ out\\:\\ 0\\.005430872840112531\ \(0\)\
\-\ is\\:\\ 0\\.0054066420998531315\ \(0\)\
\-\ radiation\\:\\ 0\\.005392790864542955\ \(0\)\
\-\ superior\\:\\ 0\\.005247584032796522\ \(0\)\
\-\ day\\:\\ 0\\.005217230441063326\ \(0\)\
\-\ during\\:\\ 0\\.005028863942161169\ \(0\)\
\-\ fat\\:\\ 0\\.004997908313233911\ \(0\)\
\-\ 6\\:\\ 0\\.004907923387259374\ \(0\)\
\-\ wall\\:\\ 0\\.0047599213850745125\ \(0\)\
\-\ lymphoma\\:\\ 0\\.004696535835364396\ \(0\)\
\-\ weeks\\:\\ 0\\.0046639956863483625\ \(0\)\
\-\ 4\\:\\ 0\\.004578792125344318\ \(0\)\
\-\ however\\:\\ 0\\.004575707799225136\ \(0\)\
\-\ high\\:\\ 0\\.004497203963609261\ \(0\)\
\-\ trauma\\:\\ 0\\.004494247657226787\ \(0\)\
\-\ cell\\:\\ 0\\.004438924445349012\ \(0\)\
\-\ over\\:\\ 0\\.004183928057961466\ \(0\)\
\-\ consistent\\:\\ 0\\.004029419747752314\ \(0\)\
\-\ increased\\:\\ 0\\.004020163041922415\ \(0\)\
\-\ man\\:\\ 0\\.003886407390557691\ \(0\)\
\-\ 3\\:\\ 0\\.003848029859051038\ \(0\)\
\-\ other\\:\\ 0\\.0037877664398124015\ \(0\)\
\-\ can\\:\\ 0\\.003727350677825134\ \(0\)\
\-\ present\\:\\ 0\\.003711555296022463\ \(0\)\
\-\ it\\:\\ 0\\.0036939392010250324\ \(0\)\
\-\ case\\:\\ 0\\.003595200832437059\ \(0\)\
\-\ \\-\\:\\ 0\\.0035225547282853147\ \(0\)\
\-\ but\\:\\ 0\\.003504814040449111\ \(0\)\
\-\ of\\:\\ 0\\.003360686561480436\ \(0\)\
\-\ to\\:\\ 0\\.003285139295715279\ \(0\)\
\-\ in\\:\\ 0\\.0032415171549250383\ \(0\)\
\-\ also\\:\\ 0\\.0032396530647502914\ \(0\)\
\-\ a\\:\\ 0\\.003050767706296933\ \(0\)\
\-\ on\\:\\ 0\\.0027841962014054926\ \(0\)\
\-\ \\(\\:\\ 0\\.002778314331707156\ \(0\)\
\-\ \\)\\:\\ 0\\.0027443757388973273\ \(0\)\
\-\ normal\\:\\ 0\\.0025761777973059637\ \(0\)\
\-\ with\\:\\ 0\\.0024750883403630523\ \(0\)\
\-\ an\\:\\ 0\\.0022724324313167883\ \(0\)\
\-\ at\\:\\ 0\\.0022264676015992945\ \(0\)\
\-\ \\:\\:\\ 0\\.0021736054153666637\ \(0\)\
\-\ the\\:\\ 0\\.002126912072363474\ \(0\)\
\-\ this\\:\\ 0\\.0018483407948348713\ \(0\)\
\-\ left\\:\\ 0\\.00183866397937099\ \(0\)\
\-\ no\\:\\ 0\\.0016547002898150039\ \(0\)\
\-\ \\.\\:\\ 0\\.0012288300956773712\ \(0\)\
